MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

– Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market (“NASDAQ”). As part of this up-listing strategy in the United States, MindMed has submitted an application to list its subordinate voting shares on NASDAQ. Continue reading “MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor”

Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets

 — Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), today announced the Company has formed a special committee to evaluate a number of options to increase shareholders value. Topics that the special committee will discuss include, but limited to, a potential spin out of certain company assets. Currently, the company owns andContinue reading “Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets”

Yield Growth Announces Name Change and Provides Corporate Update

 – August 13, 2020) –  The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) (the “Company“) announces that it will be changing its corporate name to Better Plant Sciences Inc. to reflect its strategic focus on the fast-growing market for plant-based consumer products. The Company’s new stock symbol on the CSE will be “PLNT“, and the name changeContinue reading “Yield Growth Announces Name Change and Provides Corporate Update”

Hollister Biosciences Inc. Subsidiary AlphaMind Brands Inc. Plans to Launch Initial Medicinal Mushroom Based Product Line

VANCOUVER, BC, June 4, 2020 /CNW/ – Hollister Biosciences Inc. (CSE: HOLL) (OTCPINK: HSTRF) (Frankfurt: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that the Company’s 100% owned subsidiary, AlphaMind Brands Inc. (“AlphaMind”) plans to launch medicinal mushroom based capsule and powder product lines.Continue reading “Hollister Biosciences Inc. Subsidiary AlphaMind Brands Inc. Plans to Launch Initial Medicinal Mushroom Based Product Line”

Newleaf Brands Announces its Move into State-of-the-art 7,500 sq. ft. Specialty Mycology R&D and Product Development Lab in Denver, Colorado

VANCOUVER, British Columbia, June 2, 2020 /CNW/ —  NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) (FSE: 0NF) (“NewLeaf Brands” or the “Company“), soon to put into effect its name change to Mydecine Group, is pleased to announce the completion of its wholly-owned and operated world class R&D Lab and Facilities focused on the mycology of the  fungtional© mushroom space. Earlier lastContinue reading “Newleaf Brands Announces its Move into State-of-the-art 7,500 sq. ft. Specialty Mycology R&D and Product Development Lab in Denver, Colorado”

NeonMind Taking Steps to Prove Psilocybin Effective for Weight Loss

Vancouver, British Columbia–(Newsfile Corp. – May 21, 2020) –  The Yield Growth Corp. (CSE :BOSS) (OTCQB: BOSQF) (FSE: YG3) majority owned subsidiary NeonMind Biosciences Inc. (“NeonMind“) has taken further steps towards commencing its clinical studies to confirm that psilocybin (a compound in psychedelic mushrooms) is an effective treatment for food cravings and weight loss. NeonMind has nowContinue reading “NeonMind Taking Steps to Prove Psilocybin Effective for Weight Loss”

NEONMIND COMPLETES DESIGN OF PRECLINICAL PSILOCYBIN PSYCHEDELIC MUSHROOM STUDY

May 14, 2020 – Vancouver, BC: The Yield Growth  Corp. (CSE:BOSS) (OTCQB:BOSQF) (FE:YG3) announces its majority owned subsidiary NeonMind has completed the design of a preclinical study to confirm that psilocybin (found in psychedelic mushrooms) is an effective treatment for weight loss and food craving. NeonMind engaged Translational Life Sciences Inc. (“TLS”), a contract research organization, to designContinue reading “NEONMIND COMPLETES DESIGN OF PRECLINICAL PSILOCYBIN PSYCHEDELIC MUSHROOM STUDY”

NewLeaf Brands Announces Appointment of Former Manager of Ebbu & Co-founder of Mydecine, Damon Michaels, to the Role of Chief Operations Officer (“COO”)

VANCOUVER, British Columbia, May 11, 2020 /CNW/ — NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) (FSE:0NF) (“NewLeaf Brands” or the “Company“) is pleased to announce that it has appointed Damon Michaels to the position of Chief Operations Officer (COO). Mr. Michaels previously served on the management team of Ebbu, a leading multi-platform cannabinoid research and technology firm based in Colorado. Prior to Ebbu’sContinue reading “NewLeaf Brands Announces Appointment of Former Manager of Ebbu & Co-founder of Mydecine, Damon Michaels, to the Role of Chief Operations Officer (“COO”)”

Champignon Appoints Pat McCutcheon to Board of Directors

VANCOUVER, British Columbia, May 06, 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, is pleased to announce the appointmentContinue reading “Champignon Appoints Pat McCutcheon to Board of Directors”